Papillary serous cystadenocarcinoma

From WikiMD's WELLNESSPEDIA

Papillary serous cystadenocarcinoma
Ovarian serous adenocarcinoma (3).jpg
Medium power slide of ovarian serous adenocarcinoma stained using haematoxylin and eosin.



















Ovarian cancers in women aged 20+.

Papillary Serous Cystadenocarcinoma[edit]

Papillary serous cystadenocarcinomas are the most prevalent form of malignant ovarian cancer, accounting for approximately 26 percent of ovarian tumors in women over the age of 20 in the United States. Characterized by their aggressive nature, these tumors often present challenges in early detection and treatment.

Overview[edit]

Papillary serous cystadenocarcinomas are known for their malignant potential and tendency to metastasize. They are commonly diagnosed in advanced stages, as early signs of the disease are typically absent. The spread of these tumors often occurs along the peritoneum, contributing to the complexity of treatment.

Histopathology[edit]

Histopathological examination of papillary serous cystadenocarcinomas can reveal distinct features such as:

  • Psammoma bodies - Calcified structures that are often present in these types of tumors.

Diagnosis[edit]

Diagnosis of papillary serous cystadenocarcinoma typically involves a combination of:

Treatment[edit]

The standard treatment for papillary serous cystadenocarcinoma often includes:

Prognosis[edit]

The prognosis for patients with papillary serous cystadenocarcinoma can vary based on the stage at diagnosis and the effectiveness of treatment. Generally, the five-year relative survival rate serves as a benchmark for prognosis, with early detection and treatment improving outcomes.

See Also[edit]





Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.